Featured
News
First-of-its-kind framework to assess how generics manufacturers expand access to medicine
15 February 2023
Poor countries desperately need better access to generic medicines
As the Access to Medicine Foundation publishes the first ever analytical framework specifically for generic and biosimilar medicine manufacturers, Jayasree Iyer, CEO, writes for the Financial Times about why this is important.
Generic and biosimilar medicine manufacturers can play a critical role in ensuring people around the world have access to a reliable and affordable supply of quality-assured medicines. In February 2023, the Access to Medicine Foundation launched a new analytical framework to assess, track and guide manufacturers’ efforts to expand access to their products in low- and middle-income countries (LMICs), putting these companies’ central position in the global health landscape under the spotlight.
The article describes the opportunities that are available to generics companies and the need for them to make a conscious effort to address global health challenges and realise their potential as key players in access to medicine.
"We know this is possible, because generics companies are already experts at delivering lower-cost treatments at scale, and have stepped up previously to address urgent issues."
Read the article on the Financial Times website.
